产品名称

CHIR 99021 dihydrochloride - CT 99021 dihydrochloride

产品货号

Axon 2435 CAS [N.A.] MF C22H18Cl2N8.2HClMW 538.26 Purity: 99% Soluble in water and DMSO Description Very potent and specific glycogen synthase kinase GSK-3 inhibitor; highly recommended tool. Water soluble hydrochloride salt of CHIR 99021 (Axon 1386, parent molecule) * CHIR99021 and PD0325901 (Axon 1408) are often used together as 2i in stem cell research (Axon 2128). *Promotion

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

CHIR 99021 dihydrochloride - CT 99021 dihydrochloride

Based on 3890 reference(s) in Google Scholar 10 10 3890

Axon 2435

CAS [N.A.]

MF C22H18Cl2N8.2HCl
MW 538.26

Purity: 99%
Soluble in water and DMSO

CHIR 99021 dihydrochloride

Description

Very potent and specific glycogen synthase kinase GSK-3 inhibitor; highly recommended tool. Water soluble hydrochloride salt of CHIR 99021 (Axon 1386, parent molecule)

* CHIR99021 and PD0325901 (Axon 1408) are often used together as 2i in stem cell research (Axon 2128).

*Promotion: Buy 2i inhibitor set | Axon 2128.

Prime Source Information:
CHIR 99021 from Axon Medchem has been procured by many labs as drug standard for generating reliable and reproducible biological data, evidenced by many recent publications. It is pure not only chemically but also biologically.

KEYWORDS: CHIR99021 HCl | supplier | GSK-3 inhibitor | CT 99021 hydrochloride supplier | CHIR99021 | CT99021 | CAS [1782235-14-6] | [1797989-42-4] | [252917-06-9] | Phosphorylation | GSK-3 | Inhibitor | water soluble | glycogen synthase kinase | stem cell | pluripotent | differentitaion | proliferation | dedifferentiation | cardiac

C Tong et al. Generating gene knockout rats by homologous recombination in embryonic stem cells. Nature Protocols 2011, 6, 827–844.

M Kawamata and T Ochiya. Generation of genetically modified rats from embryonic stem cells. PNAS 2010, 107(32), 14223-14228.

MY Chang et al. Direct Reprogramming of Rat Neural Precursor Cells and Fibroblasts into Pluripotent Stem Cells. PLoS One. 2010, 5(3), e9838.

IM Aparicio et al. Identification and regulation of glycogen synthase kinase-3 during bovine embryo development. Reproduction 2010, 140, 83-92.

B Zimmer et al. Coordinated waves of gene expression during neuronal differentiation of embryonic stem cells as basis for novel approaches to developmental neurotoxicity testing. Cell Death and Differentiation. 2011, 18, 383–395.

Q.L.Ying et al. The ground state of embryonic stem cell self-renewal. Nature. 2008, 453, 519-523.

J. Bain et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007, 408, 297-315.

D.B. Ring et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003, 52, 588-595.

A.S. Wagman et al. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr. Pharm. Des. 2004, 10, 1105-1137.

Cell Signaling & Oncology CNS Diabetes & Metabolism Immunology Pain & Inflammation Stem Cell GSK-3 Wnt-β-Catenin PI3K-Akt-mTOR EC 2.7.11.26

GSK-3 inhibitor

Chemical name

6-{2-[4-(2,4-Dichloro-phenyl)-5-(5-methyl-1H-imidazol-2-yl)-pyrimidin-2-ylamino]-ethylamino}-nicotinonitrile dihydrochloride

Parent CAS No.

[252917-06-9]

产品资料